Enterprise Value
2.378B
Cash
6.536B
Avg Qtr Burn
-191.3M
Short % of Float
11.52%
Insider Ownership
22.39%
Institutional Own.
72.57%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VTAMA (Tapinarof) Details Psoriasis | Approved Quarterly sales | |
VTAMA (Tapinarof) Details Atopic dermatitis | PDUFA Approval decision | |
Brepocitinib Details Systemic lupus erythematosus, Chronic non-infectious uveitis, Dermatomyositis | Phase 3 Data readout | |
Batoclimab Details Eye disease , Thyroid Eye Disease | Phase 3 Data readout | |
Batoclimab Details Myasthenia gravis | Phase 3 Data readout | |
RVT-3101 Details Ulcerative colitis | Phase 3 Initiation | |
RVT-3101 Details Crohns disease | Phase 2 Data readout | |
Namilumab Details Sarcoidosis | Phase 2 Data readout | |
RVT-2001 Details Myelodysplastic syndrome | Failed Discontinued |